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Nuclear RNA export mediated by the HIV-1 Rev protein is inhibited by chimeric proteins in which the wild-type Rev protein
is covalently linked to amino acid sequences of the NS1 protein of influenza A virus (NS1A protein), a protein that inhibits
nuclear RNA export. These chimeric molecules function not only in cis but also in trans: they inhibit nuclear RNA export
mediated by Rev protein molecules that are not covalently linked to the NS1A protein sequence. Here we show that inhibition
occurs with a NS1-Rev chimera in which the 78 amino-terminal amino acids of the NS1A protein comprising its entire
RNA-binding domain is deleted, thereby establishing that this carboxyl portion of the NS1A protein can function as an
independent effector domain. The mechanism by which this NS1-Rev chimera inhibits Rev function in trans was determined.
The Rev sequence in this chimera oligomerizes with Rev molecules in trans, and the resulting mixed oligomers are retained
in the nucleus because the nuclear retention activity of the NS1 effector domain is dominant over the nuclear transport
activity of the Rev effector domain. Binding of the FG-containing nucleoporin-like Rab protein to this NS1-Rev chimera, as
measured in yeast two-hybrid assays, is much stronger than that to the Rev protein itself, yet nuclear export does not occur
in the presence of the chimera. Unexpectedly, the introduction of specific mutations into the NS1A portion of this NS1-Rev
chimera not only restores Rev-mediated nuclear export of RNA but also eliminates detectable Rab binding, indicating that this
nuclear export can occur without detectable Rab binding. A different NS1-Rev chimera, one in which the NS1A protein is
full-length but contains a mutated RNA-binding domain, effectively inhibits Rev-mediated nuclear export of RNA without
blocking the nuclear export of the Rev protein, indicating that nuclear export of the carrier Rev protein can be uncoupled from
nuclear export of its passenger RNA. © 1998 Academic Press
INTRODUCTION
The vast majority of the RNAs that are synthesized in
the nucleus are exported to the cytoplasm through large,
complex nuclear pore complexes (NPCs) that span the
nuclear double membrane (Fischer et al., 1996; Gorlich
and Mattaj, 1996; Izaurralde and Mattaj, 1995). Recent
evidence indicates that nuclear export of RNAs, which is
energy-dependent, is mediated by one or more of the
proteins that are specifically associated with these
RNAs. These proteins contain amino acid sequences
called nuclear export signals (NESs) that direct the pro-
tein with its attached RNA to the nuclear export pathway
(Fischer et al., 1995, 1996; Gerace, 1995; Meyer et al.,
1996; Wen et al., 1995).
Of the proteins that mediate the nuclear export of RNA,
the Rev protein of human immunodeficiency virus-1
(HIV-1) is the best understood. This 116-amino-acid pro-
tein, which is essential for virus replication, facilitates the
nuclear export of unspliced and partially spliced HIV-1
pre-mRNAs that encode virus structural proteins (Cullen,
1995; Emerman et al., 1989; Felber et al., 1989; Hammar-
skjold et al., 1989; Malim et al., 1989a). In the absence of
the Rev protein, HIV-1 pre-mRNAs containing splice sites
are retained in the nucleus because they are bound to
spliceosomes where they undergo splicing.
The Rev protein has essentially two functional do-
mains as defined by mutational analysis (Cullen, 1995;
Malim et al., 1989b). The RNA-binding domain near the
amino terminus specifically interacts with a RNA target in
the viral pre-mRNA (called the Rev response element, or
RRE) (Daly et al., 1989; Malim et al., 1989a; Zapp and
Green, 1989) and also serves as a nuclear localization
signal (NLS). The Rev protein functions as an oligomer,
and the amino acid sequences needed for oligomeriza-
tion include those in the RNA-binding domain as well as
those immediately flanking the RNA-binding domain
(Cole et al., 1993; Malim and Cullen, 1991; Olsen et al.,
1990). The second domain, which is in the carboxyl half
of the molecule, is not required for RNA binding but is
required for the in vivo activity of nuclear mRNA export
(Malim et al., 1991, 1989b; Venkatesh and Chinnadurai,
1990). The effector domain consists of only 10 amino
acids, LPPLERLTLD, and the preservation of the leucines
(Ls) at positions 4, 7, and 9 in this sequence is essential
for function. For example, when the LE sequence at
positions 4 and 5 is changed to DL, the resulting Rev
M10 mutant lacks activity in nuclear RNA export. The
effector domain also participates in oligomerization in
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vivo but not in vitro (Bogerd and Greene, 1993; Madore et
al., 1994). Nonetheless, the RevM10 protein, which con-
tains a loss of function mutation in the effector domain,
forms mixed, nonfunctional oligomers with wild-type Rev
protein in vivo and acts as a trans-dominant inhibitor of
the nuclear export of RRE-containing RNA mediated by
wild-type Rev protein (Malim et al., 1989b; Mermer et al.,
1990; Venkatesh and Chinnadurai, 1990; Hope et al.,
1992; Stauber et al., 1995).
Recent results have elucidated important aspects of
the mechanism of action of the Rev effector domain. The
10-amino-acid Rev effector domain sequence has been
shown to be a NES that directs the protein with its
attached RNA to the nuclear export pathway (Fischer et
al., 1995, 1996; Gerace, 1995; Meyer et al., 1996; Wen et
al., 1995). The same effector domain mutations, e.g., the
M10 mutation, that inactivate the activity of the full-length
Rev protein in nuclear RNA export also inactivate the
NES activity of this 10-amino-acid sequence. The full-
length Rev protein, which contains a NLS as well as a
NES, shuttles between the nucleus and the cytoplasm,
and the M10 mutation eliminates the nuclear export leg
of this shuttling activity (Kalland et al., 1994; Meyer and
Malim, 1994; Richard et al., 1994; Stauber et al., 1995). It
has been postulated that these shuttling Rev protein
molecules are transporting nuclear RRE-containing
RNAs molecules to the cytoplasm through NPCs and
then returning to the nucleus through NPCs to pick up
more of the same RNA molecules for transport.
Two types of molecules that bind to the Rev effector
domain have been identified: the eukaryotic initiation
factor 5A (eIF-5A) (Bevec et al., 1996; Ruhl et al., 1993)
and cellular proteins that contain a series of FG repeats
characteristic of the nuclear pore proteins called FG
nucleoporins (Bogerd et al., 1995; Fritz et al., 1995; Stutz
et al., 1995, 1996). The latter proteins were identified in
yeast two-hybrid assays. One of these proteins has been
called Rab (Rev activation domain-binding protein) (Bog-
erd et al., 1995). Evidence suggests that the binding of a
nucleoporin-like molecule such as Rab to the Rev effec-
tor domain is required for Rev function. The same effec-
tor domain mutations that inactivate the activity of the
full-length Rev protein in nuclear RNA export also abro-
gate the binding of the nucleoporin-like protein to the
Rev protein, as determined in yeast two-hybrid assays.
These results have led to the hypothesis that Rab or
another FG-containing nucleoporin binds to the Rev ef-
fector domain and mediates its nuclear export through
the NPCs (Fischer et al., 1996; Gerace, 1995; Gorlich and
Mattaj, 1996). However, while the present paper was
under review, a different cellular receptor for Rev was
identified (Fornerod et al., 1997; Ossareh-Nazari et al.,
1997; Stade et al., 1997) (see Discussion).
The NS1 protein of influenza A virus (NS1A protein) also
regulates the nuclear export of RNA. This protein is an
unique posttranscriptional regulator that interacts with at
least two nuclear functions of the cell (Alonso-Caplen et al.,
1992; Fortes et al., 1994; Qiu and Krug, 1994; Qiu et al., 1995;
Lu et al., 1994). Specifically, it inhibits the nuclear export of
poly(A)-containing mRNAs and inhibits pre-mRNA splicing.
Mutational analysis has shown that the 237-amino-acid
NS1A protein contains two domains that are required for
both of these in vivo activities: an RNA-binding domain near
the amino-terminal end (amino acids 19–38) and a domain
in the carboxyl half of the molecule (amino acids 134–161)
that is not required for RNA binding (Qian et al., 1994). The
RNA-binding domain binds to poly(A) or to a specific stem-
bulge in the spliceosomal U6 snRNA to inhibit the nuclear
export of mRNA or to inhibit pre-mRNA splicing, respec-
tively (Qiu and Krug, 1994; Qiu et al., 1995). The NS1A
protein functions as a dimer, and mutational analysis indi-
cates that the RNA-binding and dimerization domains are
coincident (Nemeroff et al., 1995). The fragment of the NS1A
protein composed of its 73 amino-terminal amino acids
possesses the RNA-binding and dimerization activities of
the full-length protein, indicating that this fragment func-
tions as an RNA-binding and dimerization domain indepen-
dently of the rest of the protein (Qian et al., 1995). Based on
analogy with the Rev protein of HIV-1, we postulated that the
second domain in the NS1A protein is the effector domain
that interacts with cellular proteins to mediate the nuclear
retention of mRNAs and the inhibition of pre-mRNA splicing
(Qian et al., 1994).
A chimeric protein in which the NS1A protein is co-
valently linked to the wild-type Rev protein effectively
inhibits the function of wild-type Rev protein in nuclear
RNA export (Qian et al., 1996). In this particular NS1-Rev
chimera the NS1A RNA-binding domain is mutationally
inactivated, so that the Rev RNA-binding domain is the
only functional RNA-binding domain in the chimera (Qian
et al., 1996). In transfection experiments this chimera is
at least as effective as the RevM10 mutant protein in
inhibiting the function of wild-type Rev protein. Both in cis
and in the presence of a second plasmid encoding wild-
type Rev protein (i.e., in trans), the majority of an RRE-
containing RNA is retained in the nucleus instead of
being exported to the cytoplasm. In addition, this chi-
meric protein effectively inhibits the production of HIV-1
in tissue culture cells transfected with an infectious mo-
lecular clone of HIV-1 DNA. We proposed a mechanism
for how the NS1-Rev chimera could function in trans: the
wild-type Rev sequence in the NS1-Rev chimera would
oligomerize with other wild-type Rev molecules, and the
resulting mixed oligomers would be retained in the nu-
cleus because the nuclear retention activity of the NS1
effector domain in these mixed oligomers is dominant
over the nuclear transport activity of the Rev effector
domain.
The present study was undertaken to assess the va-
lidity of this postulated mechanism. For most of our
experiments we employ a different NS1-Rev chimera,
one in which the amino-terminal amino acids of the
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NS1A protein comprising its entire RNA-binding domain
are deleted. This strategy allowed us to achieve an
additional goal: the demonstration that the carboxyl por-
tion of the NS1A protein lacking its 78 amino-terminal
amino acids can function as an independent effector
domain. In addition, we verify aspects of our postulate for
the mechanism of action of an NS1-Rev chimera: the Rev
sequence in this chimera oligomerizes with other Rev
molecules in trans, and the resulting mixed oligomers
are retained in the nucleus. Nuclear retention occurs
even though binding of the FG-containing nucleoporin-
like Rab protein to this NS1-Rev chimera, as measured in
yeast two-hybrid assays, is much stronger than that to
the Rev protein itself. We obtained a surprising result: by
introducing specific mutations into the NS1A portion of
this NS1-Rev chimera, we show that Rev-mediated nu-
clear export of RNA can occur without detectable Rab
binding. Another unexpected result was obtained using
the original NS1-Rev chimera in which the NS1A protein
RNA-binding domain contains an inactivating mutation.
Surprisingly, this chimera effectively inhibits Rev-medi-
ated nuclear export of RNA without blocking the nuclear
export of the Rev protein. The RevM10 mutant protein
functions in the same way. We discuss the implications
of these unexpected results for the mechanism of the
nuclear export of the HIV-1 Rev protein and its passenger
RRE-containing RNA.
RESULTS
A NS1-Rev chimera containing a NS1A protein
sequence lacking the entirety of its RNA-binding
domain inhibits Rev function in cis and in trans
To identify the NS1A sequence that functions as an
effector domain independently of the entirety of the NS1A
RNA-binding domain, we constructed NS1-Rev chimeras
in which we linked various lengths of the carboxyl end of
the NS1A protein to the Rev protein and determined
whether such chimeras inhibited Rev function in trans,
i.e., nuclear RNA export mediated by Rev protein mole-
cules that were not covalently linked to the NS1A protein
sequence. Transfection experiments carried out in hu-
man 293 cells (Fig. 1A) showed that in the absence of
both the Rev protein and a NS1-Rev chimera the majority
(91%) of unspliced, RRE-containing tat mRNA (tat(u)) was
retained in the nucleus (lanes 1 and 2), as expected for
a pre-mRNA containing functional splice sites (Malim et
al., 1989a, 1991). In the presence of the wild-type Rev
protein (pcRev plasmid), the majority (80%) of the un-
spliced tat mRNA was exported to the cytoplasm (lanes
3 and 4), demonstrating the nuclear export activity of the
Rev protein. The first NS1-Rev chimera tested in this
assay lacked the 78 amino-terminal amino acids of the
NS1A protein and hence the entirety of the NS1A RNA-
binding domain (lanes 5 and 6). When this NS1-Rev
(NS1(79-231)-Rev) plasmid and the pcRev plasmid (at a
three to one molar ratio) were cotransfected into 293
cells, the majority (81%) of the unspliced tat mRNA was
retained in the nucleus. This dramatic change in the
nuclear/cytoplasmic distribution of unspliced tat mRNA
indicates that Rev function provided by the pcRev plas-
mid in trans has been blocked by the presence of the
NS1(79-231)-Rev protein. This result was similar to that
obtained with the chimera used in our previously exper-
iments, a NS1-Rev chimera (NS1RM-Rev) in which the
NS1A protein contains an inactivating mutation in its
RNA-binding domain (Qian et al., 1996). When the
NS1RM-Rev and the pcRev plasmid (at a three to one
molar ratio) were cotransfected into 293 cells, 70% of
unspliced tat mRNA was retained in the nucleus (lanes 7
and 8). Both NS1-Rev chimeras inhibited the function,
and not the synthesis, of the Rev protein: immunoblotting
demonstrated that the same amount of the Rev protein
was present in the absence and the presence of the
NS1-Rev chimeras (Fig. 1B). Also, the amount of the
NS1(79-231)-Rev chimera was the similar to that of the
NS1RM-Rev chimera.
The NS1A protein sequence in the NS1(79-231)-Rev
(Fig. 1A, lanes 9 and 10) and NS1RM-Rev (lanes 11 and
12) chimeric proteins also inhibited the function of the
covalently linked, wild-type Rev sequence in cis. In cells
transfected with a plasmid encoding either of these chi-
meras in the absence of the pcRev plasmid, 70–80% of
unspliced tat mRNA was retained in the nucleus.
The NS1(79-231) sequence inhibited Rev function in
trans whether it was covalently linked to the amino ter-
minus or the carboxy terminus of the Rev protein: the
majority of unspliced tat mRNA was in the nucleus (Fig.
1C, lanes 1–4). Chimeras in which the linkage was at the
amino terminus of the Rev protein were marginally more
effective in inhibiting Rev function in trans, and all sub-
sequent experiments utilized chimeras containing this
linkage.
Shortening of the 79-231 NS1A protein sequence in
the NS1-Rev chimera by only 16 amino acids at either the
NS1A amino or carboxyl end rendered the chimera inac-
tive in inhibiting Rev function in trans (Fig. 1C, lanes 5–8).
When the plasmid encoding a chimera with either of
these shortened NS1A sequences was cotransfected
with the pcRev plasmid (at a three to one ratio), 80–85%
of unspliced tat mRNA was transported to the cytoplasm.
Consequently, the entire 79-231 NS1A sequence is re-
quired for inhibition of Rev function by the chimera,
consistent with the entirety of this sequence constituting
the functional NS1A effector domain. Shortening the 79-
231 NS1A sequence in the NS1-Rev chimera by only 16
amino acids also rendered it inactive in inhibiting the
function of Rev in cis (lanes 9 and 10). The Rev sequence
covalently linked to this slightly shorter NS1A sequence
was active: 80% of unspliced tat mRNA was transported
to the cytoplasm. Thus, covalent linkage of a long NS1A
sequence to the amino terminus of the Rev protein does
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not cause cis inhibition of the function of the covalently
linked Rev protein unless the NS1A sequence has been
shown to contain a functional effector domain as estab-
lished in the trans assay.
By mutational analysis of the full-length NS1A protein the
effector domain sequence required for inhibiting nuclear
mRNA export has been mapped to the region extending
from amino acids 134 to 161 (Qian et al., 1994). Mutations in
this region abrogate the ability of the full-length NS1A
protein to inhibit the nuclear export of poly(A)-containing
mRNAs. The results of Fig. 1 indicate that the region of the
NS1A protein that can function as an independent effector
domain in the NS1-Rev chimeras extends beyond these
boundaries and encompasses amino acids 79 through 231.
If these two assays are measuring the same NS1A effector
domain function, then the same amino acid sequence
(amino acids 134 to 161) that is required for the effector
domain function of the full-length NS1A protein should
also be required for the inhibition of Rev activity mediated
by the independent NS1A effector domain region in the
NS1(79-231)-Rev chimera.
To determine whether this is the case, seven muta-
tions (Ala-Ala substitutions) that had been used previ-
ously to map the effector domain sequence of the NS1A
protein itself (Qian et al., 1994) were introduced into the
NS1A sequence of the NS1(79-231)-Rev chimera (Fig.
2A). Immunoblotting demonstrated that similar amounts
of all the chimeras were produced in the transfected
cells (data not shown). Those mutations (12 through 14)
that are located in the 134- to 161-amino-acid region of
the NS1A sequence rendered the NS1(79-231)-Rev chi-
meras inactive in blocking Rev activity in both cis and
trans: Rev-mediated nuclear export of unspliced tat
mRNA was not inhibited by these chimeras (Figs. 2B and
2C, lanes 1–6). In contrast, mutations 15 through 18 in the
NS1A protein sequence had no significant effect on the
activity of the NS1(79-231)-Rev chimeras in blocking Rev
activity in cis and trans: unspliced tat mRNA was re-
tained in the nucleus by these chimeras (lanes 7–14).
Thus, as is the case for the full-length NS1A protein itself
(Qian et al., 1994), it can be concluded that the NS1A
mRNA that was in the nucleus is indicated under the appropriate lanes.
(B) The pBC12 plasmid encoding the Rev protein (pcRev) (5 mg) was
transfected into 293 cells either alone (lane 1) or with the pBC12
plasmid encoding NS1RM-Rev (15 mg) (lane 2) or NS1(79-231)-Rev (15
mg) (lane 3). Control cells (lane 4) were not transfected. At 40 h
posttransfection, the proteins in the total cell extract were analyzed by
gel electrophoresis followed by ECL(Amersham) immunoblotting using
a polyclonal anti-Rev antiserum. (C) 293 cells were transfected with 5
mg of the plasmid (pgtat) encoding unspliced tat mRNA and the pBC12
plasmids encoding both NS1(79-231)-Rev (15 mg) and Rev (5 mg) (lanes
1 and 2); both Rev-NS1(79-231) (15 mg) and Rev(5 mg) (lanes 3 and 4);
both NS1(95-231)-Rev (15 mg) and Rev (5 mg) (lanes 5 and 6); both
NS1(79-215)-Rev (15 mg) and Rev (5 mg) (lanes 7 and 8); only NS1(79-
215)-Rev (15 mg) (lanes 9 and 10). The amount of unspliced tat mRNA in
the nucleus (N) and cytoplasm (C) was determined by S1 analysis.
FIG. 1. A NS1-Rev chimera in which the NS1A protein portion lacks
its amino-terminal 78 amino acids inhibits the nuclear RNA export
function of Rev. (A). 293 cells in 60-mm culture dishes were transfected
with 5 mg of the plasmid (pgtat) encoding unspliced tat mRNA (tat(u))
either alone (lanes 1 and 2) or with the indicated pBC12 plasmid
encoding Rev (5 mg) (pcRev) (lanes 3 and 4); both NS1(79-231)-Rev (15
mg) and Rev (5 mg) (lanes 5 and 6); both NS1RM-Rev (15 mg) and Rev
(5 mg) (lanes 7 and 8); NS1(79-231)-Rev (15 mg) (lanes 9 and 10);
NS1RM-Rev (15 mg) (lanes 11 and 12). At 40 h posttransfection, the cells
were fractionated into nuclei and cytoplasm, and the nuclear (N) and
cytoplasmic (C) RNAs were subjected to S1 analysis using a labeled
DNA probe specific for tat(u). The percentage of the unspliced tat
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sequence required for the effector function of the
NS1(79-231)-Rev chimera maps to the NS1A region ex-
tending from amino acids 134 to 161. It should be em-
phasized that these mutations in the NS1A sequence
had the same effect on both the cis and the trans activ-
ities of the NS1(79-231)-Rev chimera. In particular, the
loss of cis as well as trans activity by mutations 12
through 14 reinforces the conclusion that an NS1A se-
quence causes cis inhibition of the function of the co-
valently linked Rev protein only when the NS1A se-
quence contains a functional effector domain, as estab-
lished in the trans assay.
The NS1(79-231)-Rev chimera binds Rev proteins
in vitro and in vivo
As the first step in our proposed mechanism for how
the NS1-Rev chimera functions in trans, the wild-type Rev
FIG. 2. The NS1A sequence required for the function of the NS1(79-231)-Rev chimera in inhibiting Rev activity maps to amino acids 134 to 161. (A).
The location of the mutations in the NS1A (NS1) portion of the NS1(79-231)-Rev chimera. The shaded region extending from amino acids 134 to 161
indicates the effector domain mapped by mutational analysis of the full-length NS1A protein. The NS1A protein sequence is linked to the Rev protein
via a two-amino-acid linker (threonine–proline) (Qian et al., 1996). (B) cis and (C) trans inhibition of the nuclear RNA export function of Rev. 293 cells
were cotransfected with 5 mg of the plasmid (pgtat) encoding unspliced tat mRNA (tat(u)), 15 mg of the pBC12 plasmid encoding a NS1(79-231)-Rev
chimera containing the indicated mutation in the NS1A protein sequence, and in (C) 5 mg of the pcRev plasmid. At 40 h posttransfection, the cells
were fractionated into nuclei and cytoplasm, and the nuclear (N) and cytoplasmic (C) RNAs were subjected to S1 analysis using a labeled DNA probe
specific for tat(u).
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sequence in the NS1(79-231)-Rev chimera would be ex-
pected to oligomerize with other wild-type Rev molecules
(Qian et al., 1996). To measure the binding of the Rev
protein to a NS1-Rev chimeric protein in vitro, a GST
‘‘pull-down’’ experiment was carried out (Fig. 3). Each of
the indicated 35S-labeled chimeric proteins was mixed
with purified GST-Rev that was bound to glutathione
agarose beads, and the amount of the radiolabeled chi-
meric protein that bound to the GST-Rev protein was
determined. Like the Rev protein itself (lanes 1 and 2), all
the NS1-Rev chimeric proteins tested bound to the Rev
protein (lanes 5–12). The NS1-Rev chimeras bound to the
Rev protein whether they are active (lanes 5, 6, 11, and
12) or inactive (lanes 7–10) in the in vivo blocking of Rev
function in trans. The Rev sequence in these chimeras
was required for their binding to the GST-Rev protein: the
NS1(79-231) sequence alone lacking any Rev sequence
did not bind to the Rev protein (lanes 3 and 4).
For the analysis of interactions in vivo, we used indi-
rect immunofluorescence and confocal microscopy of
transfected cells to determine whether the Rev protein
and the NS1(79-231)-Rev chimera colocalized in the nu-
clei of the cells. To distinguish the Rev protein from the
Rev sequence in the chimera, the Rev protein contained
an influenza virus hemagglutinin (HA) epitope at its car-
boxyl terminus (Fig. 4). In the absence of the RevHA
protein, the NS1(79-231)-Rev chimera was spread
throughout the cell. In contrast, in cotransfected cells
expressing both the RevHA and NS1(79-231)-Rev chi-
meric proteins, the chimera was found almost totally in
the nucleus where it colocalized with the RevHA protein.
This colocalization indicated that the RevHA protein was
associated with the NS1(79-231)-Rev chimera, and that
the resulting protein complex was localized in the nu-
cleus, where the RevHA protein itself in the absence of
the chimera was also found.
The NS1(79-231)-Rev chimera inhibits the nuclear
export of the Rev protein
In accordance with the basic hypothesis for the nu-
clear export of RNA, our expectation was that the inhibi-
tion of Rev-mediated nuclear export of RNA in trans by
the NS1(79-231)-Rev chimera resulted from the nuclear
FIG. 3. The Rev protein binds to NS1-Rev chimeric proteins in vitro. (A) Schematic diagram of glutathione selection assay. (B) Each of the indicated
35S-labeled proteins (20 ml) was incubated with 1 mg of purified GST-Rev protein and 20 ml of glutathione Sepharose 4B beads. The labeled protein
eluted from the beads was analyzed by polyacrylamide gel electrophoresis. S, selected protein; U, unselected protein. Protein molecular weight
standards are indicated.
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retention of the complexes formed between the Rev
protein and this NS1-Rev chimera. To determine whether
this was the case, we determined whether these com-
plexes were exported from the nucleus, using two as-
says for nuclear export. In one assay, actinomycin D was
added to the transfected cells because it has been
FIG. 5. Actinomycin D shuttling assay: the nuclear export leg of Rev protein shuttling is blocked by the NS1(79-231)-Rev chimera. 293 cells were
transfected with the indicated pBC12 plasmid encoding RevHA (5 mg) (A); both RevHA (5 mg) and NS1(79-231)-Rev (15 mg) (B); both RevHA (5 mg) and
NS1M14(79-231)-Rev (15 mg) (C). At 40 h posttransfection, CM followed by actinomycin D was added to one set of cells (1ActD), which were incubated
3 h in the presence of actinomycin D. Control cells (2ActD) were incubated with only CM. RevHA and the NS1(79-231)-Rev chimera (not shown) were
detected by indirect immunofluorescence. The corresponding phase-contrast pictures are presented for each culture. The arrows denote the nuclei
of the cells in which the RevHA was detected by immunofluoresence.
FIG. 4. The NS1(79-231)-Rev chimera forms complexes with the Rev protein, and the complexes are localized in the nucleus. 293 cells were were
transfected with a pBC12 plasmid encoding NS1(79-231)-Rev (15 mg) (A) and were treated with anti-NS1 antiserum and rhodamine-conjugated
antibody. Other 293 cells were cotransfected with two pBC12 plasmids, one encoding RevHA (5 mg) and one encoding NS1(79-231)-Rev (15 mg) (B).
The cells were incubated with the two primary antibodies (anti-HA monoclonal antibody and anti-NS1 rabbit antiserum), then treated with two
secondary antibodies (FITC-conjugated goat anti-mouse antibody and rhodamine-conjugated goat anti-rabbit antibody), and examined using confocal
microscopy as described under Materials and Methods.
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shown that the function of the cellular RNA polymerase
II, which is inhibited by this drug, is required for the
import of the Rev protein into the nucleus, but is not
required for the export of this protein from the nucleus
(Kalland et al., 1994; Meyer and Malim, 1994; Richard et
al., 1994; Stauber et al., 1995). Consequently, any shut-
tling Rev protein-containing complexes would be ex-
ported from the nucleus to the cytoplasm, where they
would be trapped. The protein synthesis inhibitor, cyclo-
heximide, was also added prior to actinomycin D to
ensure that any Rev protein-containing complex that
might be found in the cytoplasm represented complexes
that had been exported from the nucleus rather than
newly synthesized complexes that had never entered the
nucleus. The locations of both the RevHA protein (using
HA antiserum) and the NS1(79-231)-Rev chimera (using
NS1 antiserum) were monitored with and without actino-
mycin D treatment. In cells in which both RevHA and the
NS1-Rev chimera were expressed, the two proteins be-
haved identically, indicating that the two proteins re-
mained together in complexes.
Figure 5 shows the results for the RevHA protein. In
the absence of a NS1-Rev chimera, most of the RevHA
protein was exported to the cytoplasm in the presence of
actinomycin D (Fig. 5A). This nuclear export was temper-
ature-dependent, as expected for an energy-requiring
process (data not shown). In the presence of the NS1(79-
231)-Rev chimeric protein the RevHA protein was re-
tained in the nucleus (Fig. 5B), indicating that the nuclear
export of RevHA was blocked. The introduction of a
mutation (M14) into the 134- to 161-amino-acid region of
the NS1A sequence in this chimera eliminated the ability
of the resulting chimera (NS1M14(79-231)-Rev) to block
the nuclear export of RevHA (Fig. 5C). As we have al-
ready shown (Fig. 2), such NS1A effector domain muta-
tions also rendered the resulting NS1(79-231)-Rev chi-
meric proteins inactive in blocking the Rev-mediated
nuclear export of RRE-containing RNA.
These results were confirmed using the interspecies
heterokaryon assay for Rev protein shuttling (Borer et al.,
1989; Guiochon-Mantel et al., 1991; Meyer and Malim,
1994; Pinol-Roma and Dreyfuss, 1992). In this assay,
which does not use actinomycin D, transfected human
293 cells expressing either the RevHA protein alone or
the RevHA protein plus the NS1(79-231)-Rev chimera
were fused with nonexpressing NIH3T3 (mouse) cells.
The nuclei of the NIH3T3 cells in heterokaryons could be
identified by the presence of characteristic satellite DNA
detected by Hoechst 33258 staining (Borer et al., 1989).
Consequently, any RevHA protein exported from the hu-
man 293 nuclei would be reimported into the NIH3T3
nuclei as well as the 293 nuclei (Fig. 6, NIH3T3 nuclei
indicated by arrows). Consequently, export of RevHA
from the 293 nuclei was assayed by its reimport into the
NIH3T3 nuclei. The results were identical to those ob-
tained with the actinomycin D assay. Export of RevHA
from the 293 nuclei occurred in the presence of RevHA
alone (Fig. 6A) and was blocked by the NS1(79-231)-Rev
chimera (Fig. 6B).
The relationship of the binding of Rab to NS1(79-231)-
Rev chimeras, as measured in the yeast two-hybrid
assay, to the nuclear export mediated by these
chimeras
The binding of Rab (or possibly another nucleoporin-
like protein) to the effector domain of the Rev protein has
been postulated to mediate the nuclear export of the
protein through the nuclear pore complexes (Fischer et
al., 1996; Gerace, 1995; Gorlich and Mattaj, 1996). Con-
sequently, if the NS1(79-231)-Rev chimera binds Rab
poorly, if at all, this might explain the lack of nuclear
export of the mixed oligomers that contain this chimera
and the Rev protein. To assess this possibility, we used
FIG. 6. Interspecies heterokaryon assay for Rev protein shuttling
confirms the results of the actinomycin D shuttling assay. Human 293
cells were transfected with the indicated pBC12 plasmid encoding
RevHA (5 mg) (A) or both RevHA (5 mg) and NS1(79-231)-Rev (15 mg) (B).
At 40 h posttransfection, an equal number of mouse NIH 3T3 cells was
added. After a 3-h incubation in the presence of CM, cell fusion was
induced with 50% PEG. RevHA was detected by indirect immunofluo-
rescence. Hoechst 33258 fluoresence was used to visualize DNA
(Borer et al., 1989). The corresponding phase-contrast pictures are
presented for each culture. The NIH3T3 nuclei in heterokaryons are
indicated by arrows.
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a yeast two-hybrid assay (Fields and Song, 1989; Nem-
eroff et al., 1995) to measure the strength of the interac-
tion of Rab with the Rev and NS1(79-231)-Rev chimeric
proteins (Table 1). The Rab protein was fused to the VP16
activation domain, and the Rev and the NS1A-containing
chimeric proteins were fused to the Gal4 DNA-binding
domain. Immunoblotting demonstrated that the levels of
synthesis of the various fusion proteins containing the
Gal4 DNA-binding domain were similar (Fig. 7).
Contrary to our expectations, Rab bound to the NS1(79-
231)-Rev chimeric protein more strongly (about seven-fold
stronger) than to the Rev protein itself (Table 1). Although
Rab bound only weakly to the NS1A protein, the strong
binding of Rab to the NS1(79-231)-Rev chimera required the
effector domain of the NS1A protein sequences of the
chimera. Any mutation (12, 13, or 14) in the 134- to 161-
amino-acid region of the NS1A effector domain eliminated
essentially all Rab binding to the NS1(79-231)-Rev chimera,
as well as the inhibition of the nuclear export of tat mRNA
mediated by the Rev protein. In particular, no detectable
Rab binding was observed with mutations 13 or 14. Hence,
Rev-mediated nuclear export of RNA occurred in the ab-
sence of detectable Rab binding. In contrast, mutations
(M15, M16, M17, or M18) in other regions of the 79-231
amino acid NS1A sequence had little, or no, effect on the
strong binding of Rab to the NS1(79-231)-Rev chimera, and
these chimeras effectively blocked Rev-mediated nuclear
export of unspliced tat mRNA.
The strong binding of Rab to the NS1(79-231)-Rev
chimera also required the Rev effector domain: the M10
mutation in the Rev protein eliminated Rab binding to the
chimera (Table 1). Consequently, strong binding of the
Rab protein to the NS1(79-231)-Rev chimera results from
a synergism between the NS1A and Rev effector do-
mains. With both RevM10 and the NS1(79-231)-RevM10
chimera, the absence of detectable Rab binding corre-
lated with the absence of Rev-mediated nuclear export of
unspliced tat mRNA, whereas with the NS1(79-231)-Rev
chimeras containing mutation 13 or 14 in the NS1A se-
quence, the absence of detectable Rab binding corre-
lated with the presence of Rev-mediated nuclear export
of unspliced tat mRNA.
TABLE 1
Interaction of Rab with Rev and NS1-Rev Chimeras
Protein fused to
b-Galactosidase
activitya
Nuclear export
of unspliced
tat mRNA
Activation
domain
DNA binding
domain
None None !1 NA
Rab Rev 78 1
Rab NS1 2.2 2
Rab NS1(79-231)-Rev 557 2
Rab NS1M12(79-231)-Rev 1 1
Rab NS1M13(79-231)-Rev ,1 1
Rab NS1M14(79-231)-Rev ,1 1
Rab NS1M15(79-231)-Rev 441 2
Rab NS1M16(79-231)-Rev 532 2
Rab NS1M17(79-231)-Rev 553 2
Rab NS1M18(79-231)-Rev 510 2
Rab NS1(79-231)-RevM10 ,1 2
Rab RevM10 ,1 2
Rab NS1RM-Rev 150 2
a Average of three yeast two-hybrid assays. Variation in assays was
not more than 15% of the average.
FIG. 7. The levels of synthesis in yeast cells of the various fusion proteins containing the Gal4 DNA-binding domain were similar. Rev and various
NS1(79-231)-Rev genes were fused with the Gal4 DNA-binding domain (Gal4BD) genes in the pMA424 vector. These constructs were transformed
into yeast host strain GGY:171. The transformed colonies were grown in (-His) selective media for 2 days and the total cell extracts were analyzed
by immunoblotting using polyclonal anti-Rev antiserum.
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Because the Rev protein has been shown to bind to
FG repeat-containing nucleoporins in addition to Rab
(Stutz et al., 1996), we determined whether other such
nucleoporins bound to the NS1(79-231)-Rev chimeras in
the same way as did the Rab nucleoporin-like molecule
(Table 2). We chose the two mammalian nucleoporins,
hCAN and rNup98, that have been reported to have the
strongest interaction with the Rev protein (Stutz et al.,
1996). Each of these mammalian nucleoporins bound to
the NS1(79-231)-Rev chimeric protein more strongly than
to the Rev protein itself (Table 2), as was also the case
for the binding of the Rab protein. The introduction of
mutation 14 into the NS1A sequence of the NS1(79-231)-
Rev chimera caused a very large (93–98%) decrease in
the binding of hCAN and rNUP98 to the chimera. Thus,
2–7% residual binding of these two mammalian nucleo-
porins was detected, whereas this NS1A mutation elim-
inated detectable Rab binding. Hence, Rev-mediated nu-
clear export of RNA occurred in the absence of detect-
able Rab binding and in the presence of greatly reduced
hCAN and rNUP98 binding to the chimera. The M10
mutation in the Rev sequence of the NS1(79-231)-Rev
chimera eliminated all detectable binding of hCAN and
rNup98, as was the case for Rab binding.
Comparison of the inhibitory mechanism of NS1(79-
231)-Rev to that of NS1RM-Rev and RevM10
The RevM10 mutant protein and the NS1RM-Rev chi-
mera, both of which inhibit Rev-mediated nuclear export
of RRE-containing RNA (Malim et al., 1989b; Mermer et
al., 1990; Venkatesh and Chinnadurai, 1990; Hope et al.,
1992; Stauber et al., 1995; Qian et al., 1996; present
study), share properties with the NS1(79-231)-Rev chi-
mera. Thus, the RevM10 mutant protein forms oligomers
with wild-type Rev protein in vitro and in vivo (Hope et al.,
1992; Malim and Cullen, 1991). Similarly, the NS1RM-Rev
chimera binds to wild-type Rev protein in vitro (Fig. 3). In
addition, as shown by indirect immunofluorescence and
confocal microscopy of transfected cells (Fig. 8), the
NS1RM-Rev chimera associates with the Rev protein in
vivo. In the absence of the RevHA protein, the NS1RM-
Rev chimera was almost totally in the cytoplasm. In
contrast, in cotransfected cells expressing both the
RevHA and NS1RM-Rev chimeric proteins, the chimera
was found almost totally in the nucleus where it colocal-
ized with the RevHA protein. The Rab protein also binds
to the NS1RM-Rev chimera, about twofold more strongly
than to the Rev protein itself (Table 1).
Based on the above results, we anticipated that both the
RevM10 protein and the NS1RM-Rev chimera would func-
tion like the NS1(79-231)-Rev chimera and would therefore
inhibit Rev-mediated nuclear export of RNA by retaining the
Rev protein in the nucleus with its bound passenger RNA.
Accordingly, we determined whether RevM10 and the
NS1RM-Rev chimera blocked the nuclear export of the Rev
protein. Unlike the wild-type RevHA protein (Fig. 5A), the
RevM10 protein was not exported to the cytoplasm in the
presence of actinomycin D (Fig. 9A),12 as previously shown
by others (Meyer and Malim, 1994; Stauber et al., 1995).
Surprisingly, in cells in which both the RevM10 and wild-
type RevHA proteins were expressed, nearly all of wild-type
RevHA was exported to the cytoplasm (Fig. 9B), indicating
that the RevM10 protein does not block the nuclear export
of the carrier Rev protein itself, though it blocks Rev-medi-
ated nuclear export of RNA. Similarly, most of the RevHA
was also exported to the cytoplasm in the presence of the
NS1RM-Rev chimeric protein (Fig. 9C), which is present in
cotransfected cells in an amount similar to that of the
NS1(79-231)-Rev chimera (Fig. 1B). Hence, this chimeric
protein, which blocks Rev-mediated nuclear export of RRE-
containing RNA (Qian et al., 1996; present study, Fig. 1A),
does not block the nuclear export of the carrier Rev protein
itself. The heterokaryon assay confirmed that wild-type
RevHA was exported to the cytoplasm in the presence of
either the RevM10 protein or the NS1RM-Rev chimeric pro-
tein (data not shown). These results provide strong evi-
dence that the mechanism by which RevM10 and the
NS1RM-Rev chimera inhibits Rev-mediated nuclear export
of RNA differs from the inhibitory mechanism occurring in
the presence of the NS1(79-231)-Rev chimera.
DISCUSSION
The identification of the functionally independent
effector domain of the influenza A virus NS1 protein
using NS1-Rev chimeras
The present results demonstrate that the sequence of
the NS1 protein of influenza A virus (NS1A protein) ex-
tending from amino acids 79 to 231 constitutes the inde-
pendent effector domain of this protein. Thus, this NS1A
amino acid sequence functions with a heterologous
RNA-binding domain, the Rev RNA-binding domain, to
cause RRE-containing RNA to be retained in the nucleus
TABLE 2
Interaction of Other Nucleoporins with Rev and NS1-Rev Chimeras
Protein fused to
b-Galactosidase
activitya
Nuclear export
of unspliced
tat mRNA
Activation
domain
DNA binding
domain
hCAN Rev 236 1
hCAN NS1(79-231)-Rev 895 2
hCAN NS1M14(79-231)-Rev 19 1
hCAN NS1(79-231)-RevM10 ,1 2
rNup98 Rev 1368 1
rNup98 NS1(79-231)-Rev 1877 2
rNup98 NS1M14(79-231)-Rev 131 1
rNup98 NS1(79-231)-RevM10 ,1 2
a Average of three yeast two-hybrid assays. Variation in assays was
not more than 15% of the average.
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even in the presence of the Rev effector domain, which
by itself facilitates the nuclear export of RRE-containing
RNA. Clearly, we can conclude that the NS1A effector
domain is dominant over the Rev effector domain in
controlling the nuclear export of this RNA. A shorter
NS1A sequence lacks effector domain function, as re-
moval of 16 amino acids from either end of this NS1A
sequence eliminates nuclear retention activity in the
NS1-Rev chimera. Though the entirety of this NS1A se-
quence is required for independent effector domain func-
tion, the only point mutations that inactivate effector
domain function are localized in one portion of this se-
quence, extending from amino acids 134 to 161 (Qian et
al., 1994; present study). Perhaps the amino acids from
134 to 161 constitute the region that primarily interacts
with the host proteins that are required for the nuclear
FIG. 9. The nuclear export leg of Rev protein shuttling is not blocked by either the RevM10 mutant protein or the NS1RM-Rev chimera. Human 293
cells were transfected with the indicated pBC12 plasmid encoding RevM10 (15 mg) (A); both RevM10 (15 mg) and RevHA (5 mg) (B); both NS1RM-Rev
(15 mg) and RevHA (5 mg) (C). The actinomycin D assay was carried out as described in the legend to Fig. 5. Indirect immunofluorescence was used
to detect RevHA (HA monoclonal antibody) and RevM10 (polyclonal anti-Rev antiserum). The corresponding phase-contrast pictures are presented
for each culture. The arrows denote the nuclei of the cells in which RevHA was detected by immunofluorescence.
FIG. 8. The NS1RM-Rev chimera forms complexes with the Rev protein, and the complexes are localized in the nucleus. 293 cells were were
transfected with a pBC12 plasmid encoding NS1RM-Rev (15 mg) (A) and were treated with anti-NS1 antiserum and rhodamine-conjugated antibody.
Other 293 cells were cotransfected with two pBC12 plasmids, one encoding RevHA (5 mg) and one encoding NS1RM-Rev (15 mg) (B). Indirect
immunofluorescence and confocal microscopy were carried out as described in the legend to Fig. 4.
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retention of RNA, whereas the other amino acids in the
independent effector domain are needed primarily to
maintain the proper fold of the polypeptide. We have now
established that the NS1A protein is composed of two
independent functional domains: an RNA-binding do-
main (amino acids 1–73), which possesses the RNA-
binding and dimerization activities of the full-length pro-
tein (Qian et al., 1995); and an effector domain (amino
acids 79–231), which is capable of functioning with a
heterologous RNA-binding domain to carry out the nu-
clear export function of the full-length NS1A protein.
The 79-231 effector domain sequence of the NS1A
protein functions more efficiently in blocking nuclear
export when the entirety of the NS1A RNA-binding do-
main is deleted than when the NS1A RNA-binding do-
main is inactivated by mutation. Thus, the NS1(79-231)-
Rev chimera blocks the nuclear export of not only RRE-
containing RNA but also the carrier Rev protein itself,
whereas the NS1RM-Rev chimera blocks the nuclear
export of RRE-containing RNA mediated by the Rev pro-
tein, but does not block the nuclear export of the Rev
protein carrier itself. The decreased effectiveness of the
NS1A effector domain when a mutation is introduced into
the RNA-binding domain of the full-length NS1A protein
can be attributed to the resulting changes in the folding
of the entire NS1A protein. The NS1A RNA-binding do-
main consists of a dimer that adopts a novel six-helical
chain fold (Chien et al., 1997; Liu et al., 1997). A mutation
in the RNA-binding domain disrupts the dimerization of
the NS1A protein (Nemeroff et al., 1995), thereby also
disrupting the six-helical chain fold of this domain. This
dramatic change in protein structure in the RNA-binding
domain at the amino end of the NS1A protein might be
expected to cause changes in the folding of the rest of
the protein or to block access to the rest of the protein.
As a consequence, the effector domain in the carboxy
half of the molecule would be less functional or less
accessible. In contrast, removal of the entirety of the
RNA-binding domain would allow the NS1A effector do-
main to fold properly on its own.
The relationship of the binding of Rab to Rev-
containing proteins, as measured in the yeast two-
hybrid assay, and the nuclear export mediated by
these proteins
The present study provides another example of the
significant new information that can be obtained from an
analysis of the mechanism of action of inhibitors. We
show that the complexes that are formed in the nucleus
between the Rev protein and one chimera, NS1(79-231)-
Rev, are not exported to the cytoplasm. The block in the
nuclear export of these complexes is not due to weak, or
little, binding of the Rab protein, the FG nucleoporin-like
protein that has been presumed to mediate the nuclear
export of the Rev protein (Bogerd et al., 1995). The Rab
protein binds to both the Rev and the NS1-Rev chimera
constituents of these complexes. In fact, as measured in
yeast two-hybrid assays, the binding of Rab to the
NS1(79-231)-Rev chimera is much stronger (sevenfold
stronger) than that to the Rev protein itself. Thus, this
strong binding of Rab is not sufficient to cause nuclear
export of the chimera. In fact, it might be argued that it is
this very strong binding of Rab that is actually responsi-
ble for the block in the nuclear export of the oligomers
containing Rev and NS1(79-231)-Rev. For example, this
strong binding might inhibit the dissociation of Rab that
is required for a nuclear export process that has been
hypothesized to proceed via multiple, sequential interac-
tions of the protein with different FG nucleoporins that
span the NPCs (Gerace, 1995; Gorlich and Mattaj, 1996;
Rexach and Blobel, 1995; Stutz et al., 1996). However, this
explanation is not likely, because the HTLV-1 Rex protein,
which mediates nuclear export, binds very strongly to
Rab (Fritz et al., 1995); in yeast two-hybrid assays, we
found that this binding was about fourfold stronger than
the binding of Rab to the Rev protein. Instead, a more
likely explanation would be that the NS1 effector domain
interacts very strongly with the host nuclear proteins that
mediate the nuclear retention of the NS1 protein and that
this interaction would be dominant over the interactions
that occur in the nuclear export pathway mediated by the
effector domain of the Rev protein. This dominance
would result in the nuclear retention of NS1-Rev chime-
ras and of Rev molecules that oligomerize with the Rev
sequence in these chimeras. Also, this dominance would
not depend on whether the nuclear pathways for the
transport of spliced mRNAs (NS1 pathway) and their
unspliced precursors (Rev pathway) are different (Stutz
et al., 1996).
The stronger binding of Rab to the NS1(79-231)-Rev chi-
mera requires the effector domains of both the NS1A and
Rev proteins. A mutation in either the NS1A effector domain
(mutation 12, 13, or 14) or in the Rev effector domain (M10)
eliminates Rab binding. We can propose two hypotheses
for how the effector domain of the NS1A protein, which
inhibits rather than facilitates nuclear export, augments the
binding of Rab to this chimera. First, because the Rab
protein binds weakly to the effector domain of the NS1A
protein, it may be argued that the NS1A and Rev effector
domains in the chimera are spatially close to each other, so
that a single Rab protein molecule might be bound to two
sites on the chimeric protein molecule. An alternative pos-
sibility stems from the observation of most investigators
that Rab and other FG-containing nucleoporins do not di-
rectly bind to the Rev protein in vitro (Fritz et al., 1995; Stutz
et al., 1995, 1996; Ossareh-Nazari et al., 1997), indicating
that one or more other proteins supplied by the yeast cells
are probably required for the Rab binding measured in the
yeast two-hybrid assay. Consequently, it could be argued
that the NS1A and Rev effector domains may be synergistic:
each may bind a different subset of these putative proteins
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very strongly. Clearly, more knowledge about the functional
interactions of the NS1A and Rev effector domains with
cellular nuclear proteins is needed. Indeed, one or more of
such cellular factors that interact with the NS1A effector
domain probably plays an important role in the nuclear
retention of the NS1A protein and its bound RNA whether or
not the NS1A protein is covalently linked to the Rev protein.
By introducing specific mutations into the NS1A
portion of the NS1(79-231)-Rev chimeras, we demon-
strate that Rev-mediated nuclear export of RNA can
occur in mammalian cells even though Rab binding to
these chimeras is not detectable in yeast two-hybrid
assays. Thus, mutation 13 or 14 in the NS1A sequence
of the chimera eliminates detectable binding of Rab to
the chimera, whereas these mutant chimeras, unlike
the wild-type chimera, facilitate the nuclear export of
RRE-containing RNA. There are several possible inter-
pretations of these results. First, a trivial explanation is
that the lack of an interaction between the mutant
chimeras and Rev in yeast cells is caused by some
unusual behavior of the mutant chimeras in yeast
cells. Another possibility is that the yeast two-hybrid
system may not be sensitive enough to detect low
levels of interactions that would be sufficient to medi-
ate nuclear export in mammalian cells. Our experi-
ments with two other mammalian nucleoporins relate
to this explanation. These two nucleoporins, hCAN
and rNup98, were chosen because their binding to the
Rev protein is significantly stronger than that of Rab
(Stutz et al., 1996). We show that, as is the case with
Rab, the binding of either of these two nucleoporins to
the NS1(79-231)-Rev chimera is stronger than that to
the Rev protein itself and that the introduction of mu-
tation 14 into the NS1A sequence of the chimera
greatly reduces binding. However, presumably be-
cause of their much stronger binding, 2–7% residual
binding to the mutant chimera is detected. Although
we cannot rule out the possibility that these residual
nucleoporin molecules, or even residual Rab protein
molecules, are responsible for mediating Rev nuclear
export, it seems more reasonable that the restoration
of nuclear export by the introduction of NS1 mutation
13 or 14 would be accompanied by the increased
binding of any cellular protein that mediates nuclear
export. Therefore, the most interesting possibility is
that one or more cellular proteins other than Rab or
other nucleoporins are the cellular cofactors for Rev. In
fact, while this paper was being reviewed, several
papers provided strong evidence that a different mol-
ecule is the cellular receptor for Rev, namely, CRM1, a
protein that has sequence homolgy with a family of
proteins involved in the nuclear import of proteins
(Fornerod et al., 1997; Ossareh-Nazari et al., 1997;
Stade et al., 1997).
The dissociation of RRE-containing RNA from the
carrier Rev protein during nuclear export
Our results indicate that the NS1RM-Rev chimera and
the RevM10 protein block the nuclear export of RRE-
containing RNAs by some mechanism other than the
retention of Rev protein carrier molecules in the nucleus.
Complexes are formed between the Rev protein and the
NS1RM-Rev chimera in the nucleus, and these com-
plexes shuttle between the nucleus and cytoplasm even
though RRE-containing RNA remains in the nucleus. The
RevM10 mutant protein acts in a similar fashion. The
most likely explanation is that RRE-containing RNAs that
are initially bound to the Rev RNA-binding domains are
released during the process of nuclear export of the
mixed oligomers containing the Rev protein and either
NS1RM-Rev or RevM10. Evidence indicates that RRE-
containing RNAs in the nucleus readily bind to the Rev
RNA-binding domains in oligomers containing RevM10
or a NS1-Rev chimera. Thus, RRE-containing RNAs effi-
ciently bind to Rev-RevM10 complexes in vitro (Malim
and Cullen, 1991). Also, as shown in the present study,
RRE-containing RNAs bind to mixed oligomers contain-
ing Rev and a NS1(79-213)-Rev chimera in vivo: when the
NS1A portion of these chimeras contains mutation 12, 13,
or 14, these oligomers bind unspliced tat mRNA mole-
cules and transport them to the cytoplasm.
The logical extension of this hypothesis is that the
release of RRE-containing RNAs from the Rev RNA-bind-
ing domains of these oligomers represents an aberration
of a normal process that occurs during nuclear export of
these RNA. Normally when the complexes containing the
Rev carrier protein and its passenger RNA reach the
cytoplasmic side of the nuclear membrane, the com-
plexes must be dissociated because: (i) the freed Rev
proteins can then reenter the nucleus to carry other
RRE-containing RNAs out of the nucleus and (ii) the freed
RRE-containing RNAs can then either be translated or
incorporated as genomic RNAs into progeny virions
(Cullen, 1995). Because of the strength of the interaction
between the Rev protein and RRE-containing RNA, the
dissociation of these protein–RNA complexes would be
expected to require an active process. We propose that
this active process occurs in the NPCs themselves, nor-
mally in the region of the NPCs that is on the cytoplasmic
side of the nuclear double membrane. However, the
mixed oligomers containing the Rev protein and either
NS1RM-Rev or RevM10 are probably not transported
through the NPCs as efficiently as the Rev oligomers that
contain only one protein species. Accordingly, we pos-
tulate that the process that normally dissociates RRE-
containing RNA from the Rev RNA-binding domains in
oligomers is activated in the NPCs prematurely, before
the mixed oligomers reach the cytoplasmic side of the
nuclear double membrane. Protein–RNA dissociation in
the nuclear side of the NPCs has been documented
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previously: the SR protein hrp45 dissociates from RNA in
this region of the NPCs (Alzhanova-Ericsson et al., 1996).
In spite of their putative defects in nuclear export, the
mixed oligomers containing the Rev protein and either
the Rev M10 protein or the NS1RM-Rev chimera were
found to be exported to the cytoplasm. However, another
group of investigators found that the RevM10 protein
partially inhibited the shuttling of a fusion protein con-
taining the wild-type Rev protein linked to the green
fluorescent protein (Stauber et al., 1995). Perhaps their
results can be attributed at least in part to an additional
deleterious effect on the nuclear export of the Rev-
RevM10 oligomer caused by the large, 238-amino-acid,
green fluorescent protein that was covalently linked to
the Rev protein.
The potential of the NS1(79-231)-Rev chimera for
antiviral therapy against HIV-1
The Rev protein, which is required for HIV-1 replication
(Cullen, 1995), is a potential target for antiviral therapies.
The RevM10 mutant protein has been considered to be
the prototype trans inhibitor of Rev function and, using
gene therapy techniques, is currently in phase I clinical
trials for the treatment of AIDS patients (Malim et al.,
1992; Bridges and Sarver, 1995; Bevec et al., 1992). We
have already shown that the NS1RM-Rev chimera inhib-
its the production of HIV-1 in tissue culture cells as
effectively as RevM10 (Qian et al., 1996). Our present
results suggest that the NS1(79-231)-Rev chimera will be
a more effective inhibitor of HIV-1 replication than the
RevM10 protein, because this chimera inhibits not only
Rev-mediated nuclear export of RRE-containing RNA but
also (unlike the RevM10 protein) inhibits the nuclear
export of the Rev protein itself. Consequently, it will be of
great interest to determine the relative protective effect
of these two proteins against HIV-1 infection.
MATERIALS AND METHODS
Construction of expression vectors for NS1-Rev
chimeric proteins
The preparation of the pBC12 plasmid containing the
NS1RM-Rev chimeric gene has been described previ-
ously (Qian et al., 1996). For the preparation of pBC12
plasmids containing genes encoding chimeric proteins
in which the NS1(79-231) sequence is linked to the Rev
protein, the DNA sequence encoding amino acids 79 to
231 of the NS1A protein was amplified by PCR using
primers that generated a EagI site at the amino terminus
and an AsuII site at the carboxyl terminus. The resulting
NS1(79-231) gene was ligated to EagI–AsuII-cut pBC12
plasmid. This plasmid was used to generate genes en-
coding chimeric proteins in which Rev was linked to
either the carboxyl or the amino terminus of the NS1(79-
231) sequence. Insertion of a PCR-amplified Rev gene
containing an AsuII site at both ends produced NS1(79-
231)-Rev, and insertion of a PCR-amplified Rev gene
containing an EagI site at both ends produced Rev-
NS1(79-231). The entirety of each of the chimeric genes
was sequenced.
Detection of unspliced tat mRNA in transfected cells
Monolayers of human 293 cells were transfected with
the plasmids indicated in each figure using the calcium
phosphate method (Alonso-Caplen et al., 1992; Qian et
al., 1994). The transfected cells were collected at 40 h
posttransfection. The cells were fractionated into nuclear
and cytoplasmic fractions, and the RNAs in these two
fractions were extracted with guanidinium isothiocya-
nate. The purity of the nuclear and cytoplasmic fractions
was determined in two ways, as described previously (Lu
et al., 1994; Qian et al., 1996). Cell-equivalent amounts of
nuclear and cytoplasmic RNAs were assayed by S1 nu-
clease protection using a 59-end-labeled single-stranded
DNA probe specific for unspliced tat mRNA (Qian et al.,
1996). After S1 nuclease digestion, the protected frag-
ments were resolved by electrophoresis on a urea–poly-
acrylamide (7%) gel. After exposure of the gels to X-ray
films, the relative amounts of nuclear and cytoplasmic
unspliced tat mRNA were determined by densitometry.
For the quantitation of the Rev protein and of the NS1-Rev
chimeric protein, the proteins extracted from an aliquot
of the total cell extract were resolved on SDS-containing
14% polyacrylamide gels, which were analyzed by immu-
noblotting using a polyclonal anti-Rev antiserum (kindly
provided by Bryan Cullen, Duke University).
Glutathione sepharose affinity selection
The DNAs encoding the Rev- and NS1-containing pro-
teins indicated in Fig. 3 were subcloned into the pGEM1
vector and translated using a Promega TnT Coupled
Transcription/Translation kit and [35S]cysteine (800 Ci/
mmol). Each of these labeled proteins (20 ml) was com-
bined with purified GST-Rev protein (1 mg) and 20 ml of
glutathione Sepharose 4B (Pharmacia) as previously de-
scribed (Nemeroff et al., 1995). The labeled protein
bound to the beads was eluted by heating the beads at
95°C for 2 min in a buffer containing 5% 2-mercaptoetha-
nol. The eluate was analyzed by electrophoresis on a
15% SDS–polyacrylamide gel.
Indirect immunofluorescence and confocal
microscopy
PCR was used to link the DNA encoding the HA
peptide sequence YPYDVPDYA to the 39 end of the DNA
encoding the Rev open reading frame, and the RevHA
DNA sequence was inserted into the pBC12 plasmid.
The 293 cells, which were grown on glass coverslips,
were transfected with a pBC12 plasmid encoding either
NS1RM-Rev or NS1(79-231)-Rev or were cotransfected
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with two pBC12 plasmids, one encoding RevHA and one
encoding either NS1RM-Rev or NS1(79-231)-Rev. At 40 h
posttransfection, the cells were washed with PBS (phos-
phate-buffered saline), fixed with 3% paraformaldehyde
in PBS for 30 min, and permeabilized with 1% Triton X-100
for 5 min. The cells were then incubated with the two
primary antibodies (5 mg/ml of the 12CA5 anti-HA mono-
clonal antibody from Boehringer Mannheim; 1:400 dilu-
tion of anti-NS1 rabbit antiserum) for 1 h at 37°C. After
three washes with PBS, the cells were incubated for 1 h
at 37°C with the two secondary antibodies (1:200 dilution
of FITC-conjugated goat anti-mouse antibody; 1:200 di-
lution of rhodamine-conjugated goat anti-rabbit anti-
body). After three washes with PBS, the coverslips were
inverted and mounted on glass microscope slides. The
cells were examined using a Molecular Dynamics Con-
focal Laser Scanning Microscope equipped with Image
Space software.
Assays for nucleocytoplasmic shuttling of proteins
In one assay, actinomycin D was used to block nuclear
import of proteins (Pinol-Roma and Dreyfuss, 1992). Hu-
man 293 cells, which were grown on coverslips, were
transfected with the indicated plasmid(s). At 40 h post-
transfection, cycloheximide (CM) (50 mg/ml) was added
for 30 min, then actinomycin D (5 mg/ml) was added, and
incubation was continued for an additional 3 h. Control
cells were incubated with only CM (50 mg/ml) for 3.5 h.
RevHA and the NS1-Rev chimera were detected by indi-
rect immunofluorescence as described above, and the
cells were examined by epifluorescence using a Nikon
Microphot-FXA microscope at 300;ts magnification. In a
second assay, the interspecies heterokaryon assay (Bor-
er et al., 1989; Pinol-Roma and Dreyfuss, 1992), the hu-
man 293 cells (on coverslips) at 40 h posttransfection
were trypsinized and mixed with an equal number of
mouse NIH 3T3 cells. The cell mixture was replated and
incubated 3 h in the presence of CM (50 mg/ml). Because
of the CM treatment, all of the RevHA protein in the
human 293 cells was localized in the nucleus. Cell fusion
was induced by inverting the coverslips into a drop of
prewarmed 50% polyethylene glycol (PEG) for 2 min. The
cells were washed twice with prewarmed PBS and were
then incubated at 37°C for an additional 3 h in new
medium containing 50 mg/ml CM. RevHA was detected
by indirect immunofluorescence. To stain the DNA of the
cells, Hoechst 33258 was added at the time of incubation
with the secondary antibody (Borer et al., 1989).
Yeast two-hybrid assays
The complete open reading frames of the proteins
indicated in Table 1 were cloned into yeast vector
pMA424 (HIS3 marker). The resulting plasmids express
fusion proteins containing the above proteins linked to
the Gal4 DNA-binding domain. The yeast plasmid pVP16-
Rab (LEU2 marker), which was kindly provided by Bryan
Cullen, expresses a fusion protein containing Rab linked
to the VP16 activation domain. In Table 2, Nup98 and
CAN fragments ( kindly provided by Michael Rosbash,
Brandeis University) were fused with Gal4-acitvation do-
main gene in the pGAD424 vector. Each of the activation
domain fusion plasmids and each of the pMA424 plas-
mids were cotransfected into yeast strain GGY<171,
which carries the Gal1-lacZ reporter gene. Transfor-
mants were isolated, and the b-galactosidase levels of
the transformants were quantitated in liquid assays as
previously described (Miller, 1972; Nemeroff et al., 1995).
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